Cortiment launched in Russia

September 17, 2015, Moscow held IBD School (Inflammatory Bowel Disorder School) chaired by the head gastroenterologist of the Moscow Region, Professor Elena Belousova. NovaMedica was the general partner of this educational event that brought together over 100 gastroenterologists from Moscow and other regions of Russia.

During this event, Elena Belousova first time introduced Cortiment* to the medical society as new Rx product recently registered in Russia. In her report, she noted that Cortiment is a promising opportunity in therapy of ulcerative colitis.

NovaMedica is promoting this product in the Russian market within its gastroenterology portfolio, which also includes such products as Galstena and a line of Benegast food supplements.

*Cortiment® (multimatrix budesonide) is a new product for the Russian market designed to induce remission in patients with light and moderate ulcerative colitis.  Cortiment’s dosage of 9mg should be taken once a day, which has a proven efficacy and provides a high level of patients’ adherence to the treatment. Cortiment is a modern drug product initially registered in Netherland in late 2013. Cortiment became available for the Russian patients already in 2015.